Last updated: June 27, 2023
Sponsor: University of Monastir
Overall Status: Completed
Phase
3
Condition
Acute Pain
Pain
Treatment
Paracetamol
Paracetamol caféine
Paracetamol Codeine
Clinical Study ID
NCT05229965
Codeine-Cafeine-Paracetamol
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Age :18 years or older
- Patients presented to the emergency department with acute post-traumatic pain andresidual pain at rest and/or on movement with a numerical pain rating scale (NRS) > 3/10 on discharge.
- They all signed a written consent form.
Exclusion
Exclusion criteria:
- Self-mutilation
- Severe acute trauma that may require hospitalization
- Open or complicated fracture requiring surgical management
- Regular use of analgesics
- Any known allergy to paracetamol, caffeine or codeine
- Asthma and acute/chronic respiratory insufficiency
- Severe renal insufficiency (creatinine Cl<30 ml/min)
- Pregnant/lactating women
- Hepatic cirrhosis.
- Refusal, incapacity or difficulties to consent or to communicate
Study Design
Total Participants: 1500
Treatment Group(s): 3
Primary Treatment: Paracetamol
Phase: 3
Study Start date:
November 01, 2022
Estimated Completion Date:
June 27, 2023
Study Description
Connect with a study center
Nouira Semir
Monastir, 5000
TunisiaSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.